Skip to main content

Advertisement

SpringerLink
Log in

Late-onset panhypopituitarism in a 72-year-old male patient treated with ipilimumab for metastatic melanoma: a case report

  • Letter to the Editor
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Araujo PB, Coelho MC, Arruda M, Gadelha MR, Neto LV (2015) Ipilimumab-induced hypophysitis: review of the literature. J Endocrinol Invest 38(11):1159–1166. doi:10.1007/s40618-015-0301-z

    Article  CAS  PubMed  Google Scholar 

  2. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 21(2):371–381. doi:10.1530/ERC-13-0499

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P (2014) Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 6:230ra45. doi:10.1126/scitranslmed.3008002

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Diabetology, Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy

    G. Vancieri, A. Bellia & D. Lauro

Authors
  1. G. Vancieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Bellia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Lauro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Lauro.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

We state that all procedures performed in this study were in accordance with the ethical standards of the research committee of our Institution and with the 1964 Helsinki Declaration and its later amendments.

Informed consent

A written informed consent was obtained by the patient mentioned in this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vancieri, G., Bellia, A. & Lauro, D. Late-onset panhypopituitarism in a 72-year-old male patient treated with ipilimumab for metastatic melanoma: a case report. J Endocrinol Invest 39, 805–806 (2016). https://doi.org/10.1007/s40618-016-0439-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-016-0439-3

Keywords

Search

Navigation